novel CRC target contributing to ESCC viability. Using circular chromosome conformation capture sequencing (4C-seq) and CRISPR/Cas9 genome editing, the direct interaction between TP63 promoter and functional enhancers which is mediated by CRC TFs is identified. Deletion of each enhancer decreases expression of CRC TFs and impairs cell viability, phenocopying the knockdown of each CRC TF.
accessibility are useful to delineate the cellular cistrome and transcriptome, which exhibit prominent lineage specificity. These epigenetic characteristics are also notably altered in disease states, such as cancer. In particular, we and others have shown that the clusters of active enhancers called super-enhancers (SEs) mediate transcriptional dysregulation in human cancers (Chipumuro et al., 2014; Hnisz et al., 2013; Jiang et al., 2017; Xie et al., 2018; Yuan et al., 2017) . These SE loci are occupied by high density of lineage-or cell type-specific transcription factors (TFs), chromatin regulators and coactivators to govern gene expression networks and hence contribute profoundly to cancer biology Hnisz et al., 2017; Whyte et al., 2013) .
In several cell types (e.g., embryonic stem cells, neuroblastoma, medulloblastoma, chronic lymphocytic leukemia and T-cell acute lymphoblastic leukemia) (Boyer et al., 2005; Durbin et al., 2018; Lin et al., 2016; Ott et al., 2018; Sanda et al., 2012) , a limited number of TFs (often termed master TFs) bind to their own SEs as well as those of the other members, forming interconnected core regulatory circuitry (CRC) to regulate gene expression of themselves and the other master TFs. Based on these features, CRC TFs can be predicted mathematically by SE mapping coupled with motif enrichment analysis (Saint-Andre et al., 2016) . Functionally, CRC TFs orchestrate transcriptional dysregulation in cancer cells by cooperatively enhancing expression of an array of oncogenes via activating their SEs. Notably, this orchestration results in transcriptional addiction in cancer, which can be exploited pharmacologically. However, such a CRC program for esophageal squamous cell carcinoma (ESCC) remains unknown.
ESCC is common (more than 400,000 cases each year) and aggressive malignancy (causing almost 300,000 deaths per year), with a 5-year survival rate less than 20% Enzinger and Mayer, 2003) . Unfortunately, genome-guided therapeutic strategy is still unavailable for ESCC patients, although ESCC genomic abnormalities have been comprehensively characterized and established (Cancer Genome Atlas Research et al., 2017; Gao et al., 2014; Lin et al., 2018a; Lin et al., 2014; Lin et al., 2018b; Liu et al., 2017; Song et al., 2014) . In addition, the high-degree genomic heterogeneity of this cancer further limits application of mutational-targeted therapy. Many findings have suggested that an alternative and appealing therapeutic strategy for a heterogeneous cancer such as ESCC is to target the epigenome (Falkenberg and Johnstone, 2014; Hnisz et al., 2017; Kuhn et al., 2016; Ott et al., 2018) . In this regard, a number of epigenetic agents have been developed, including inhibitors against bromodomains and extra-terminal (BET) family proteins and histone deacetylases (HDACs). BET proteins recognize and bind to acetylated lysine residues of histone, and HDACs remove acetyl groups on an array of proteins (Belkina and Denis, 2012; Delmore et al., 2011; Falkenberg and Johnstone, 2014; Filippakopoulos et al., 2010) . Both BET and HDAC inhibitors display promising anticancer potential in various types of malignancies through perturbation of multiple components in transcriptional regulation, most notably SEs (Greer et al., 2015; Ott et al., 2018; Ozer et al., 2018; Qu et al., 2017) . Specifically, cancer-specific SEs exhibit hypersensitivity to transcriptional inhibition, a primary mechanism underlying the superior anti-tumor potency of BET and HDAC inhibitors (Chapuy et al., 2013; Hnisz et al., 2017; Jiang et al., 2017; Loven et al., 2013; Ott et al., 2018; Yuan et al., 2017) . 
RESULTS

Identification and Characterization of CRC Program in ESCC
Defining epigenomic features is instrumental for understanding gene regulatory programs. Histone markers H3K4me1 and H3K4me3 correlates with active/poised enhancers and active promoters, respectively (Heintzman et al., 2007; Heinz et al., 2015; Rada-Iglesias et al., 2011; Zentner et al., 2011) , while H3K27ac (deposited by EP300) separates active from poised regulatory elements (Creyghton et al., 2010; Heintzman et al., 2007; Visel et al., 2009 ). Using chromatin immunoprecipitation sequencing (ChIP-seq) with antibodies against H3K4me1, H3K4me3 and H3K27ac, the cis-regulatory landscapes of 8 ESCC cell lines was initially defined ( Figure 1A) .
SE-assigned genes were annotated, including well-known SCC oncogenes-TP63, SOX2, KLF5, CCAT1, CTTN, EGFR Jiang et al., 2017; Watanabe et al., 2014; Xie et al., 2018) ( Figure S1A ; Tables S1, S2 and S3). We next performed assay of transposase-accessible chromatin with sequencing (ATAC-seq), which showed high concordance with H3K4me1 and H3K27ac signals, as ATAC-seq signals were located at valley regions of H3K4me1 and H3K27ac peaks ( Figure 1A ),
suggesting that transcriptional activity is highly associated with chromatin accessibility.
To construct core regulatory circuitry (CRC) program in ESCC, we first applied
CRC_Mapper to these 8 enhancer-annotated ESCC cell lines (Figures 1B and S1A) and identified 36 candidate TFs which occurred in more than 50% at ESCC cell lines ( Figure 1C ). This result strongly supports recent findings that TP63 directly interacts with SOX2 to co-occupy and regulate hundreds of SEs in SCC cells Watanabe et al., 2014) .
As a first step to characterize CRC functions in ESCC, ChIP-seq profiles of TP63, SOX2 and KLF5, along with EP300 and RNAPII were generated and analyzed.
Conspicuous trio-binding pattern was observed for the 3 CRC members across the ESCC genome, and the majority of co-occupancy located at active enhancer elements with concordant density of ATAC-seq signals, and surrounded by exceptionally high levels of enhancer markers-H3K4me1 and H3K27ac and coactivator-EP300 (Figures 1A and 1D) . Consistent with our previous data , the majority of TP63, SOX2 and KLF5 overlapped binding sites located at enhancer regions (87.6%) ( Figure 1A ). Across the genome, trio-binding (27.9%) was more likely to associate with SEs when compared with either duo-or solo-binding (18.8% and 12.7%, respectively) ( Figure 1E ). Importantly, SE-associated genes with trio-binding had the highest expression in ESCC cells relative to those with either duo-, solo-or non-binding ( Figure 1F ), suggesting that the cooperative occupancy among CRC factors produced the highest transcriptional activity.
To determine the mechanistic basis for the cooperation and trio-binding among TP63, SOX2 and KLF5, their protein-protein interaction was examined.
Co-immunoprecipitation (Co-IP) revealed that each of TF could pull-down the other 2 proteins, demonstrating the direct interaction among master TFs in ESCC cells ( Figure 1G ). This result is also consistent with a previous study detecting the direct protein interaction between SOX2 and TP63 in SCCs based on mass spectrometry (Watanabe et al., 2014) . In addition, the presence of EP300 protein was observed in either TP63-, SOX2-or KLF5-immunoprecipitated complex ( Figure 1G ).
Close visualization confirmed prominent trio-occupancy of TP63, SOX2 and KLF5 on their own SE elements as well as others (Figures 2A and S1B (Figures 2A and S1B ), but also form interconnected co-regulatory circuitry.
The functional requirements of TP63 and SOX2 for ESCC have been established Jiang et al., 2017; Xie et al., 2018) . However, the biological significance of KLF5 in ESCC is comparably less investigated. The expression of KLF5 was initially examined, it was top ranked in ESCC samples relative to other types of cancers in either TCGA (Manuscript In Press) or Cancer Cell Line Encyclopedia (CCLE) samples ( Figure 2D ). This further supports the correlation and co-regulation between KLF5, TP63 and SOX2, since previous results showed that TP63 and SOX2 also had a prominent SCC-specific expression pattern Watanabe et al., 2014 , multiple enhancer elements were noted with reduced ATAC-seq signals upon silencing of each CRC member (red arrows, Figure 3E ).
Considering the prominent pattern of trio-occupancy of these master TFs along the genome ( Figures 1A and 1D ), their ChIP-seq data were integratively analyzed with the dynamic changes in ATAC-seq signals. Not surprisingly, the regulatory elements of trio-occupied by CRC members were overall more accessible ( Figure 3F ). More importantly, silencing of either TP63, SOX2 or KLF5 led to a more pronounced attenuation of the ATAC-seq signals at trio-occupied regions relative to non-trio-occupied regions ( Figure 3G ), suggesting that the change of accessibility was a result from their cooperative transcriptional regulation rather than indirect effects.
Collectively, these results demonstrate that through direct protein-protein interaction, TP63, SOX2 and KLF5 promote and maintain the chromatin accessibility at thousands of cis-regulatory regions, thereby orchestrating the transcriptional network in a cooperative manner in ESCC cells ( Figure 3H ).
ALDH3A1 Is a Novel Downstream Target of ESCC CRC
We next aimed to identify downstream targets trio-regulated by TP63, SOX2 and KLF5. RNA-seq analysis was performed upon independently silencing of each of TF in ESCC cells (Table S6 ) . Upon integrating RNA-seq results with ATAC-seq data, a total of 175 genes exhibited significant decreased of both mRNA expression (Table S7 ) and ATAC-seq signals ( Figure 4A ). These genes included several known TP63/SOX2 targets with prominent functions in SCC, such as TXRND1 and CCAT1 . Amongst these 175 targets, we were particularly interested in ALDH3A1 (Aldehyde Dehydrogenase 3 Family Member A1)
because it not only showed ESCC-specific expression pattern but also had highest expression in ESCC cells except for KRT6A ( Figure 4B ; Table S7 ), which encoded Keratin housekeeping protein for keratinization (Hanukoglu and Fuchs, 1983) .
We interrogated how ALDH3A1 was regulated by ESCC CRC. ChIP-seq data showed that ALDH3A1 locus was flanked by broad SE clusters (red bar, Figure 4C) , with concomitant open chromatin signals ( Figures 4C and 4D ). In comparison, the SE of ALDH3A1 had either a much weaker or undetectable H3K27ac signals in both EAC and NEM samples ( Figure 4C ), supporting an ESCC-specific regulatory mechanism. The SE constituents of ALDH3A1 (red arrows in Figure 4C ) were prominently trio-bound by all CRC members and EP300 ( Figure 4C ). More importantly, silencing of any CRC TF led to significant decreased chromatin accessibility at trio-binding regions ( Figure 4D ). These data suggest a direct regulatory function of CRC TFs on ALDH3A1 transcription, which was further supported by the result that the mRNA level of ALDH3A1 was significantly correlated with each CRC TF ( Figure 4E , data from TCGA Consistent with the enhancer profiles ( Figure 4C ), expression of ALDH3A1 was higher in ESCC than EAC samples ( Figure 4G ). IHC staining of tissue microarray showed strong expression of ALDH3A1 protein in more than half of ESCC tumors (54.5%, 30 of 55) ( Figure 4H ). In contrast, it was barely detectable in nonmalignant esophagus epithelium. To evaluate the functional significance of ALDH3A1 in ESCC cells, loss-of-function assays were performed, silencing of ALDH3A1 suppressed cell viability and clonogenic capacity ( Figures S4C and S4D ). In xenograft assays, knockdown of ALDH3A1 consistently inhibited tumor growth in vivo ( Figures 4I, 4J and S4E). Taken together, these data identified ALDH3A1 as a novel and important target of TP63, SOX2 and KLF5, which is specifically upregulated in ESCC and promotes cell proliferation of this cancer.
Mechanistic Characterization the SE Regions of TP63
To investigate further the mechanism underlying the cooperatively transcriptional regulation among CRC TFs, TP63 was selected as a study model, which itself was a CRC member and had one of the largest SE regions in several ESCC cell lines ( Figures 5A and S1B ). Our ChIP-seq data revealed that while TP63 gene was surrounded by active SEs in ESCC cells (denoted by red bars in Figure 5A ), much weaker or almost undetectable H3K27ac signal were present in NEM and EAC ( Figure 5A ). In addition, most of the SE domains were trio-bound by the three CRC TFs and EP300.
We next employed circular chromosome conformation capture sequencing (4C-seq) assays in TE5 cells to unbiasedly identify DNA regions which had physical contact with the TP63 promoter ( Figure 5B ; Table S8 ). Focusing on the top 20 most significant DNA-DNA interactions (according to q value) ( Figure 5B ), 9 of these 20 regions were located in the enhancer domains (namely, e1, e2, e4-e8, e10 and e11, 
Disruption of Functional SE Constituents Collapses ESCC CRC Program and
Consequently Inhibits ESCC proliferation
To test directly the role of candidate functional SE constituents (e2, e7 and e8) in mediating transcription of TP63, luciferase reporter assays were initially performed, and the activity of both the TP63 promoter and the three enhancers was verified ( Figures 6D and S5C) . Moreover, the reporter activities of the three enhancers reduced significantly and consistently upon silencing of each CRC member ( Figures   6D and S5C) , demonstrating that the function of e2, e7 and e8 depends on the activity of CRC TFs.
We next performed CRISPR/Cas9 genome editing and generated cell populations with deletions of either TP63 promoter or individual SE constituent (validation by Sanger sequencing, Figure S5D ). Genomic deletions were also generated in negative control regions, including a gene desert region (Des) and an adjacent region of the 
ARV-771 Evicts BRD4 Protein and Suppresses Proliferation of ESCC Cells
Given the profound role of CRC-mediated transcriptional dysregulation in ESCC cells, the potential anti-ESCC property of BET inhibition was investigated. BET-targeting compounds including competitive BET bromodomain inhibitors and BET-PROTAC degraders (proteolysis-targeting chimera), these have shown promising therapeutic activity in a variety of cancers, particularly in hematopoietic malignancies (Mazur et al., 2015; Ott et al., 2018; Ozer et al., 2018; Qu et al., 2017; Shu et al., 2016; Zanconato et al., 2018) . Initially, expression of BET proteins was examined, BRD2 and BRD4 had much greater abundance than other BET members in TCGA ESCC samples ( Figure 7A ). ChIP-seq results revealed that BRD4 was an SE-associated gene, whose SE was enriched with dense H3K27ac, H3K4me1 and ATAC-seq signals ( Figure 7B ). In contrast, these enhancer peaks were much lower in NEM sample. Moreover, four open chromatin regions were identified (e1-e4 of BRD4
in Figure 7B ) within discrete H3K27ac peaks which were trio-occupied by ESCC CRC members. Importantly, silencing any CRC member substantially decreased expression of BRD4 at both mRNA ( Figure S6A ) and protein levels ( Figures 7C and   S6B ). We did not observe SE or extensive CRC TF binding in BRD2 locus ( Figure   S6C ).
Given the prominent function of BRD4 in other cancer types, we performed a series of loss-of-function assays to explore BRD4-mediated cellular effects in ESCC.
Cell proliferation and colony formation ability were significantly suppressed upon silencing of BRD4 ( Figures 7D and S6D-S6F) , confirming that BRD4 is essential for ESCC growth. Several small-molecule compounds targeting BET proteins in ESCC cells were tested. MTT assay showed that the BET-PROTAC degraders (including ARV-771, MZ1 and ARV-825) were the most potent compounds ( Figure 7E ). Among of them, ARV-771 exhibited submicromolar IC50 in most ESCC cell lines ( Figures   7E and 7F ). As expected, ARV-771 inhibited expression of BRD4 both dose-and time-dependently ( Figure 7G ). Because ARV-771 degrades BET proteins through ubiquitin-proteasome system, this BET-targeting effect was abolished by either MG132 or Carfilzomib proteasome inhibitors ( Figure 7H ).
Synergistic Effect between BET Degrader and HDAC Inhibitor in ESCC
In addition to targeting epigenetic readers such as the BET family, inhibition of epigenetic eraser-histone deacetylases (HDACs) can have potent anti-neoplastic activity (Bolden et al., 2006; Ellis et al., 2009; Falkenberg and Johnstone, 2014) .
Recently, with the advanced understanding of noncoding genome, the effect of HDAC inhibitors on enhancer function was elucidated (Mishra et al., 2017; Sanchez et al., 2018) . Intriguingly, pharmacological screening found that HDAC inhibitors reduced TP63 stability in an ubiquitin proteasome-dependent manner (Napoli et al., 2016) . Considering that TP63 and its associated CRC program have a profound role in orchestrating ESCC transcriptome, six HDAC inhibitors were tested against ESCC cells. Three of them showed exceptional potency (IC50s: 22-88 nM), with
Romidepsin displaying the most potent activity against all of the ESCC cell lines ( Figures 8A and S7A) . Western blot showed that Romidepsin amongst all HDAC inhibitors was most powerful in degrading TP63 ( Figure 8B) . Indeed, Romidepsin at as low as 10 nM completely abolished TP63 expression ( Figure 8C ). Importantly, protein levels of the other two CRC TFs (SOX2 and KLF5) were concomitantly diminished ( Figure 8C ), again validating co-regulation and co-dependency of these CRC members. Addition of either MG132 or Carfilzomib recovered the protein levels of TP63, as well as those of SOX2 and KLF5 ( Figures 8D and S7B) , confirming that Romidepsin degrades TP63 protein through an ubiquitin-proteasome system. H3K4me3 peaks for Romidepsin, Figure S7C ]. Notably, focusing on lost peaks, ARV-771 had a more profound impact on H3K4me3+ promoter regions while
Romidepsin showed greater effect on H3K27ac+ distal enhancers ( Figures 8E and 8F ).
On the other hand, 43.0% (H3K4me3) and 57.5% (H3K27ac) of all the "lost regions" were shared between treatments by these two chemicals. These analyses together suggest that ARV-771 and Romidepsin extensively suppress the activity of cis-regulatory elements in ESCC cells. Importantly, these drugs not only co-targeted the epigenetic modification at thousands of shared noncoding regions (white fraction in Figure 8F ), but also had specific and complementary effects on a multitude of enhancers and promoters (blue and green fractions in Figure 8F ). Moreover, by integration of ATAC-seq data, we observed that 6,753 (58.0%) regions with lost accessibility elicited by silencing of TP63 also showed lose of H3K27ac signals upon administration of Romidepsin ( Figure 8G) S7D and S7E) and substantially reduced their IC50s (from 631 nM to 50 nM for ARV-771, from 22 nM to 5 nM for Romidepsin) ( Figures 7E, 8A and S7E ).
Their synergistic activity was further tested in vivo using an ESCC-derived 
DISCUSSION
By mapping the cis-regulatory landscapes and integrating expression profiles, we established ESCC-specific core regulatory circuitry (CRC) program (TP63, SOX2 and KLF5) that contributes to the ESCC tumorigenesis. ChIP-seq datasets showed that these TFs trio-occupied at the same enhancers and SEs across the ESCC genome, which were marked with dense H3K27ac, H3K4me1, EP300 and ATAC-seq signals.
Consistently, enriched binding of KLF5 has been observed in EP300-and H3K27ac-positive regions in head and neck squamous cell carcinoma (HNSCC) , indicating a similar epigenetic pattern shared by different types of squamous cell carcinomas (SCCs).
Consistent with the CRC model, TP63, SOX2 and KLF5 trio-bound to the SE elements of their own and each other's, forming an interconnected transcriptional network in an ESCC-specific manner. Importantly, silencing of any single TF collapsed the entire CRC program, which further led to reduced accessibility at thousands of chromatin elements in ESCC cells. SOX2-containing CRC (together with NANOG and OCT4) has been well-characterized in embryonic stem cells (Boyer et al., 2005; Whyte et al., 2013) . In gastric cancer, KLF5, GATA4 and GATA6 are co-regulated by physical interaction on their respective promoters (Chia et al., 2015) .
These findings suggest that the same TFs can be incorporated into different CRC programs in different cell types to regulate cell-type-specific gene expression patterns.
A key characteristic of CRC model is the formation of a feed-forward loop connecting master TFs with the SEs of each CRC member. Here, we investigated in depth how this loop controls SE-promoter interaction at the TP63 locus. 4C-seq and 3C assays together with CRISPR/Cas9 mediated genome editing showed that three SE constituents (e2, e7 and e8) interacted directly with the TP63 promoter and contributed to the transcription of TP63, as well as the other master TFs (SOX2 and KLF5 shown to be engaged in a long-range interaction with the TP63 promoter through a 3C array in squamous-like pancreatic cancer cells (Andricovich et al., 2018) , strongly supporting our unbiased 4C-seq results. Moreover, the other two functional elements (e7 and e8) were also identified previously to be occupied by TP63 itself. Specifically, TP63 binding stimulated the activity of e7 and e8, contributing functionally to the transcription of TP63 (Antonini et al., 2006; Antonini et al., 2015) , congruent with our results (Figures 6 and S5) . These findings together highlight the functions of these three SE constituents in the transcriptional activation of TP63 and consequently the entire CRC activity in ESCC.
Through integrative analysis of RNA-seq, ChIP-seq and ATAC-seq, we identified a novel and key direct target of ESCC CRC program, ALDH3A1. Notably, ALDH3A1
also had a strong cluster of ESCC-specific SEs, which were absent in either EAC or NEM samples. Knockdown of any master TF caused a dramatic reduction in ATAC-seq signals at trio-occupied SE regions of ALDH3A1 by CRC members, confirming their essential role in the direct upregulation of ALDH3A1. Functionally, ALDH3A1 was required for viability of the ESCC cells both in vitro and in vivo. As an isoenzyme of aldehyde dehydrogenase superfamily, ALDH3A1 contributes to tumorigenesis and chemoresistance of cancer cells through detoxifying various aldehydes from both endogenous and exogenous sources by oxidizing aldehydes to the corresponding acids (Kim et al., 2017; Parajuli et al., 2014; Wu et al., 2016) .
Although the functional role of ALDH3A1 in ESCC was unknown hitherto, large-scale GWAS studies have implied an association between the aldehyde-oxidizing pathway and ESCC susceptibility. Specifically, polymorphic variants of ALDH2 (associated with changes from Glu487 to Lys487) were found to induce flushing, and they were enriched in individuals of East Asian origin. Notably, these variants increased the risk for ESCC development particularly when these carriers consumed alcohol (Abnet et al., 2018; Brooks et al., 2009; Yokoyama et al., 2003) . Together with our data, these findings suggest potential biological relevance of ALDH3A1 in ESCC development which warrants further investigations.
To exploit the epigenomic dysregulation in ESCC for potential therapeutic intervention, we investigated both BET and HDAC inhibitors. BET inhibition was tested because BRD4 was highly expressed in ESCC and was identified as a direct target of ESCC CRC members. We also discovered that, a HDAC inhibitor (Romidepsin) exhibited prominent capabilities of degrading TP63 protein, and consequently destructing the entire ESCC CRC ( Figure 8C ). Not surprisingly, either ARV-771 (BET degrader) or Romidepsin elicited pronounced anti-neoplastic effect in ESCC cells, with ensuing reduction of H3K27ac and H3K4me3 signals across the genome. ARV-771 and Romidepsin co-targeted thousands of shared regulatory regions. Moreover, these two compounds exhibited differential and complementary effects on the ESCC epigenome, with ARV-771 preferentially impairing promoter functions while Romidepsin favoring the inhibition of distal enhancers. Supporting our data, HDAC inhibitors attenuated acetylation at distal regulatory elements and decreased expression of associated genes in colorectal and pancreatic cancer cells (Mishra et al., 2017; Sanchez et al., 2018) . In the present study, the function of Romidepsin on distal enhancers is likely to be attributed to the potency of degradation of TP63 as evidenced by the shared changes in enhancer loci ( Figure 8G ). Based on their differential and complementary effects on the ESCC epigenome, we tested and confirmed a synergistic anti-ESCC effect when ARV-771 and Romidepsin were combined both in vitro and in vivo. Likewise, the enhanced anti-proliferative activity of a BET protein with an HDAC was demonstrated as a potential therapeutic strategy for both pancreatic cancer (Mazur et al., 2015) and Myc-induced murine lymphoma (Bhadury et al., 2014) . Together, this combinatorial strategy deserves further pre-clinical and clinical testing for ESCC treatment.
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